ClinicalTrials.gg
CompletedNCT04388878Updated Jul 12, 2022

Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants

A Phase 1 interventional study of PF-07054894 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, tolerability, and PK of single escalating doses and multiple escalating doses of PF-07054894.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female (of non-child bearing potential) participants must be 18 to 55 years of age, inclusive, and with of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  • Male and female of non-child bearing potential participants who are overtly healthy as determined by medical evaluation.
  • Participants must be willing to avoid direct sunlight exposure or any high intensity ultraviolet light exposure, from admission to FU1 and to apply sun screen/lotion with a high sun protection factor, as appropriate.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, immunological/rheumatological, or allergic diseases.
  • Evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB), history of infection, , or .
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Have a history of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
  • History of phototoxicity and photosensitivity.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    PF-07054894

    Participants will receive single or multiple ascending doses of oral PF-07054894

    Drug: PF-07054894

  • Placebo comparator
    Placebo

    Participants will receive matching placebo

    Drug: Placebo

Interventions

  • Participants will receive oral ascending doses

  • DrugPlacebo

    Participants will receive matching placebo

06

What researchers measure

Primary outcomes

  1. AEs following Single ascending dose (SAD)

    Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs

    Time frame: Day 1 up to Day 28 (SAD)

  2. AEs following multiple ascending dose (MAD)

    Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs

    Time frame: Day 1 up to Day 42 (MAD)

  3. Percentage of subjects with laboratory abnormalities

    Time frame: Day 1 up to Day 7 (SAD) or Day 1 up to Day 21 (MAD)

  4. Number of subjects with change from baseline in vital signs

    Number of subjects with change from baseline of blood pressure, pulse rate, and oral temperature

    Time frame: Day 1 up to Day 7 (SAD) or Day 1 up to Day 21 (MAD)

  5. Number of subjects with change from baseline in electrocardiogram (ECG) parameters

    Time frame: Day 1 up to Day 7 (SAD) or Day 1 up to Day 21 (MAD)

Secondary outcomes

  1. Maximum Plasma concentration (Cmax)

    Maximum observed plasma concentration (Cmax)

    Time frame: Day 1 (SAD) or Day 1 and Day 14 (MAD)

  2. Time to reach plasma Cmax (Tmax)

    Time to reach maximum observed plasma concentration (Tmax)

    Time frame: Day 1 (SAD) or Day 1 and Day 14 (MAD)

  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 up to Day 3 (SAD)

  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞).

    Time frame: Day 1 up to Day 3 (SAD)

  5. Dose normalized Cmax (Cmax(dn))

    Dose normalized maximum plasma concentration (Cmax(dn))

    Time frame: Day 1 (SAD) or Day 1 and Day 14 (MAD)

  6. Apparent Oral Clearance (CL/F)

    Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed and a quantitative measure of the rate at which the drug is removed from the blood.

    Time frame: Day 1 (SAD) or Day 14 (MAD)

  7. Apparent Volume of Distribution (Vz/F)

    Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Day 1 (SAD) or Day 14 (MAD)

  8. Single dose and Multiple Dose PK half-life (t½)

    Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 (SAD) or Day 14 (MAD)

  9. Observed Accumulation Ratio for Cmax (Rac,Cmax)

    Accumulation ratio based on maximum plasma concentration (Cmax) calculated as: Rac,Cmax = Cmax at steady state (ss) divided by Cmax at first dose.

    Time frame: MAD, Day 14

  10. Observed Accumulation Ratio for AUCτau (Rac, AUCτau)

    Accumulation ratio calculated as, Rac obtained from Area Under the Concentration Time Curve (AUCτau) from time 0-τau (Day 14) divided by AUC from time 0-τau (Day 1).

    Time frame: MAD, Day 14

  11. Area Under the Curve From Time Zero to End of Dosing Interval (AUCτau)

    Area under the concentration curve from time 0 to end of dosing interval (AUCτau), where dosing interval is 12 hours.

    Time frame: Day 1 and Day 14 of MAD

  12. Minimum Observed Plasma Trough Concentration (Cmin)

    Minimum plasma concentration over the dosing interval τau (12 hour) from first dose to last dose

    Time frame: Day 1 up to Day 14 of MAD

  13. Multiple dose PK/AUCτau (dn)

    Dose normalized area under the curve over the dosing interval τau (12 hour) after the first and last dose (AUCτau (dn))

    Time frame: Day 1 and Day 14 of MAD

  14. Cumulative Amount of Drug Recovered Unchanged in Urine during dosing interval (Ae,τau)

    Cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval is 12 hours (Ae,τau)

    Time frame: MAD, Day 14

  15. Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τau (Ae,τau%)

    Percent of dose recovered in urine as unchanged drug over the dosing interval (Ae,τau%)

    Time frame: MAD, Day 14

  16. Renal Clearance (Clr)

    Renal clearance calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae,τau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτau), where dosing interval is 12 hours.

    Time frame: MAD, Day 14

07

Study locations

1 site
  • Brussels Clinical Research Unit
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jun 2022, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 14, 2020
StartActual
Jul 27, 2020
Primary completionActual
Jun 21, 2022
CompletionActual
Jun 21, 2022
Last update
Jul 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04388878
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 14, 2020
Start date
Jul 27, 2020
Primary completion
Jun 21, 2022
Completion
Jun 21, 2022
Last update
Jul 12, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07054894

Start the discussion